Go Pro
OTCMKTS:DGNOF

DIAGNOS Q3 2025 Earnings Report

DIAGNOS logo
$0.34 0.00 (-0.47%)
As of 03:34 PM Eastern

DIAGNOS EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DIAGNOS Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DIAGNOS Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

DIAGNOS' next earnings date is estimated for Tuesday, December 1, 2026, based on past reporting schedules.

Conference Call Resources

DIAGNOS Earnings Headlines

These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.tc pixel
See More DIAGNOS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DIAGNOS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DIAGNOS and other key companies, straight to your email.

About DIAGNOS

DIAGNOS (OTCMKTS:DGNOF) is a Canadian healthcare technology company focused on the early detection of medical conditions through artificial intelligence, image processing and telemedicine. The company develops and commercializes tools designed to help healthcare providers identify disease at an earlier stage and support access to diagnostic services.

Its principal platform, CARA (Computer Assisted Retinal Analysis), analyzes retinal images to assist with the screening of conditions such as diabetic retinopathy and other eye diseases. DIAGNOS has also developed related screening and remote-care capabilities intended to support patient assessment in clinics, pharmacies and other healthcare settings.

Founded in 1998 and headquartered in Brossard, Quebec, DIAGNOS has pursued commercial and screening initiatives in Canada and international markets. The company’s solutions are designed for use by healthcare organizations seeking scalable, technology-assisted screening and telemedicine services.

View DIAGNOS Profile